Market Cap 814.17M
Revenue (ttm) 164.07M
Net Income (ttm) -372.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -226.84%
Debt to Equity Ratio 0.00
Volume 6,542,645
Avg Vol 11,087,786
Day's Range N/A - N/A
Shares Out 361.85M
Stochastic %K 50%
Beta 0.83
Analysts Sell
Price Target $9.10

Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanom...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 260 7120
Address:
825 Industrial Road, Suite 100, San Carlos, United States
Joe521
Joe521 Oct. 27 at 6:23 PM
$IOVA The demand is there. They need to be more selective and educate patients and physicians on benefits of early treatment. Iova is consistently losing 25-26% potential revenue due to patient drop and manufacturing failure. Huge room for improvement and needed for profitability. Move ASAP when frontline fails.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Oct. 27 at 6:17 PM
0 · Reply
UnderLion16
UnderLion16 Oct. 27 at 5:41 PM
$IOVA https://www.linkedin.com/posts/iovance_please-join-us-in-supporting-the-melanoma-activity-7388605913240059904-mr0M?utm_source=share&utm_medium=member_desktop&rcm=ACoAAEsd0XQB-kbKVWH1Winw4qDcCWoIeyftplo
1 · Reply
StockednLoaded
StockednLoaded Oct. 27 at 5:29 PM
$IOVA - The min viable amount of TIL’s to be in-spec commercially is 5-6x > clinicals. This is not a scientific necessity but rather a regulatory and biz decision. Iova is punting near term rev bc it doesn’t matter. Apologies to all you margin watchers (and fudsters). It’s being strategically suppressed. By de-risking the launch (reducing product variability and in-field commercial failures) you protect LT value and brand. That’s why you’re seeing RW #’s trump clinicals’ bc on avg it’s superior product. ATC’s can administer OOS to help simulate operational flows at larger vols while keeping a governor on Rev. I bet they took a minimum TIL cell viability that is easily and routinely achievable in 1L since that’s all they care about mnfg at scale—and that’s why they’re partnering with McKesson bc eventually (once de-risked) the TIL commercial model becomes decentralized at the community level instead of closed-loop at the academic.
1 · Reply
beachsidefreddy
beachsidefreddy Oct. 27 at 5:28 PM
$IOVA the jan $3 calls are offered at $.60 now thats up .20!!!!!!!!!!!!!
0 · Reply
tedevan
tedevan Oct. 27 at 5:20 PM
0 · Reply
ZeroSumTeam
ZeroSumTeam Oct. 27 at 5:15 PM
$IOVA Big big move incoming Coiled and ready to pop $2.50-2.70 by end of week should be easy
0 · Reply
LostChang3
LostChang3 Oct. 27 at 5:15 PM
$IOVA so maybe the trick is to just not look at it on here ever. Then it might rise
0 · Reply
ECHorizon
ECHorizon Oct. 27 at 4:59 PM
$IOVA Folks, what do you think? 🤔 IMO, it could be possible that the ESMO and SITC presentations are calculated to signal what’s coming. ESMO’s focus was on Amtagvi survival data (17-26% cure rates, 89-month lifetime OS) targets payers, while SITC’s focus is on efficacy - rash-efficacy link empowers clinicians, priming NSCLC/endometrial catalysts. ESMO (survival data for payers) + SITC (rash-efficacy for clinicians) = primed monster data/growth. Then the other items: $100M+ annual savings (announced Aug 7, via Q4 workforce/R&D cuts) will be in full effect soon/MFG efficiency gains to help improve margins/InspiroGene by McKesson partnership; plus IP moat (patents to 2044) secure TIL manufacturing. Long-term, If (a huge IF) catalysts hit, profitability could arrive by Q4 27 with $50M+ net income on expansions. Sustained profitability in 28 with $200M annual profits. A lot could go wrong, but it’s possible. 🤷‍♂️
0 · Reply
egolden08
egolden08 Oct. 27 at 4:58 PM
$IOVA she looking thicc 😂
0 · Reply
Latest News on IOVA
Iovance Biotherapeutics to Present at Upcoming Conferences

Aug 29, 2025, 8:30 AM EDT - 2 months ago

Iovance Biotherapeutics to Present at Upcoming Conferences


Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

Jul 10, 2025, 4:01 PM EDT - 3 months ago

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.


Iovance Biotherapeutics to Present at Upcoming Conference

Jun 10, 2025, 8:45 AM EDT - 4 months ago

Iovance Biotherapeutics to Present at Upcoming Conference


Joe521
Joe521 Oct. 27 at 6:23 PM
$IOVA The demand is there. They need to be more selective and educate patients and physicians on benefits of early treatment. Iova is consistently losing 25-26% potential revenue due to patient drop and manufacturing failure. Huge room for improvement and needed for profitability. Move ASAP when frontline fails.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Oct. 27 at 6:17 PM
0 · Reply
UnderLion16
UnderLion16 Oct. 27 at 5:41 PM
$IOVA https://www.linkedin.com/posts/iovance_please-join-us-in-supporting-the-melanoma-activity-7388605913240059904-mr0M?utm_source=share&utm_medium=member_desktop&rcm=ACoAAEsd0XQB-kbKVWH1Winw4qDcCWoIeyftplo
1 · Reply
StockednLoaded
StockednLoaded Oct. 27 at 5:29 PM
$IOVA - The min viable amount of TIL’s to be in-spec commercially is 5-6x > clinicals. This is not a scientific necessity but rather a regulatory and biz decision. Iova is punting near term rev bc it doesn’t matter. Apologies to all you margin watchers (and fudsters). It’s being strategically suppressed. By de-risking the launch (reducing product variability and in-field commercial failures) you protect LT value and brand. That’s why you’re seeing RW #’s trump clinicals’ bc on avg it’s superior product. ATC’s can administer OOS to help simulate operational flows at larger vols while keeping a governor on Rev. I bet they took a minimum TIL cell viability that is easily and routinely achievable in 1L since that’s all they care about mnfg at scale—and that’s why they’re partnering with McKesson bc eventually (once de-risked) the TIL commercial model becomes decentralized at the community level instead of closed-loop at the academic.
1 · Reply
beachsidefreddy
beachsidefreddy Oct. 27 at 5:28 PM
$IOVA the jan $3 calls are offered at $.60 now thats up .20!!!!!!!!!!!!!
0 · Reply
tedevan
tedevan Oct. 27 at 5:20 PM
0 · Reply
ZeroSumTeam
ZeroSumTeam Oct. 27 at 5:15 PM
$IOVA Big big move incoming Coiled and ready to pop $2.50-2.70 by end of week should be easy
0 · Reply
LostChang3
LostChang3 Oct. 27 at 5:15 PM
$IOVA so maybe the trick is to just not look at it on here ever. Then it might rise
0 · Reply
ECHorizon
ECHorizon Oct. 27 at 4:59 PM
$IOVA Folks, what do you think? 🤔 IMO, it could be possible that the ESMO and SITC presentations are calculated to signal what’s coming. ESMO’s focus was on Amtagvi survival data (17-26% cure rates, 89-month lifetime OS) targets payers, while SITC’s focus is on efficacy - rash-efficacy link empowers clinicians, priming NSCLC/endometrial catalysts. ESMO (survival data for payers) + SITC (rash-efficacy for clinicians) = primed monster data/growth. Then the other items: $100M+ annual savings (announced Aug 7, via Q4 workforce/R&D cuts) will be in full effect soon/MFG efficiency gains to help improve margins/InspiroGene by McKesson partnership; plus IP moat (patents to 2044) secure TIL manufacturing. Long-term, If (a huge IF) catalysts hit, profitability could arrive by Q4 27 with $50M+ net income on expansions. Sustained profitability in 28 with $200M annual profits. A lot could go wrong, but it’s possible. 🤷‍♂️
0 · Reply
egolden08
egolden08 Oct. 27 at 4:58 PM
$IOVA she looking thicc 😂
0 · Reply
Nibbler
Nibbler Oct. 27 at 4:51 PM
$IOVA Xbi screamin..... Iova...
1 · Reply
The_Scientist
The_Scientist Oct. 27 at 4:45 PM
$IOVA Two cents higher—sound the horn, A legend in the market’s born. Raise your glass, oh mighty crowd, Two cents richer—say it loud.
2 · Reply
Revaluation
Revaluation Oct. 27 at 4:19 PM
$IOVA For the scientists out there - Are the commercial specs more stringent than the trial specs? If not, wouldn’t they have been running into this OOS issue for the past 5 years when producing treatment for trials? Seems like an odd thing to come out of nowhere and only affect the commercial product…
3 · Reply
KingNYC
KingNYC Oct. 27 at 4:10 PM
$IOVA They buy and it goes a bit up, they immediately pause it, and they let it go down and they buy more again. The loading game! Keep loading slowly to control the price to buy cheap before the big news breaks. The price must stay around here until this will pump to two digits.
0 · Reply
ZeroSumTeam
ZeroSumTeam Oct. 27 at 3:57 PM
$FUN $KRNT $JD $GPUS $IOVA LFG! 🔥 🐂 🆙
0 · Reply
Polip
Polip Oct. 27 at 3:52 PM
$IOVA I think Bristol Myers Squibb really needs this asset badly
1 · Reply
ClearCities
ClearCities Oct. 27 at 3:36 PM
$IOVA If this somehow happens or remotely close to his predictions, i will change my religion to biotechscanner
2 · Reply
ZeroSumTeam
ZeroSumTeam Oct. 27 at 3:21 PM
$KRNT $RIVN $GPUS $ENPH $IOVA 🔥 🚀 🌙
1 · Reply
Glenolla
Glenolla Oct. 27 at 3:19 PM
$IOVA Fk it! Bought more! She got a run in her before EOY.
0 · Reply
Fire_Truck
Fire_Truck Oct. 27 at 3:19 PM
$IOVA We should start to see some 🧨💥 in Nov. Dec.
0 · Reply
Jgockman
Jgockman Oct. 27 at 3:12 PM
$IOVA what happened to all the buyout discussions? Seem to have evaporated. Will this thing get bought out?
2 · Reply
profits7
profits7 Oct. 27 at 3:11 PM
0 · Reply